List view / Grid view
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
Vaxart's application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
Earlier this year, Johnson & Johnson announced the first major regulatory approval of a vaccine developed by Janssen for the prevention of Ebola. Nikki Withers spoke with the Global Head of Vaccines, Johan Van Hoof, to discover what technologies were used and how they are now being leveraged to develop…
Therapyx and Intravacc will jointly develop NGoXIM, a microsphere vaccine which is designed to stimulate adaptive immunity against gonorrhoea.
Grant Courtney explains why traceability is vital for the current pandemic as it would guarantee that COVID-19 vaccines are safe, effective and suitably distributed.
A new vaccine platform using self-assembling peptide nanofibres tagged with antigens has been tested successfully in mice, eliciting a strong immune response.
The European Investment Bank (EIB) will provide three €25 million instalments to support CureVac’s vaccine development and expansion to mRNA production facilities.
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
A Phase I clinical trial to test Imperial College London's COVID-19 vaccine candidate has been initiated, with the first patient dosed.
This in-depth focus includes articles detailing five important considerations for European companies entering the US biosimilar market and explaining why virally vectored DNA and mRNA vaccines could prevent the spread of COVID-19.
Dr Saurabh Kumar Banerjee outlines the impact of COVID-19 on immunisation programmes in India and how organisations can hope to mitigate the consequences of missed vaccine doses.
Researchers have begun research to find how sustainable cold chain delivery systems for a COVID-19 vaccine can be established in resource-poor countries.
A polio vaccine designed to be incapable of evolving the ability to cause disease in humans has shown promise in a Phase I clinical trial.
A clinical trial to study a MERS vaccine has demonstrated success, say researchers, suggesting their technology could be repurposed to halt the spread of COVID-19.
